Organigram Global (OGI) Stock Price, News & Analysis

Company Overview

Organigram Global Inc. (NASDAQ: OGI) is a Canadian licensed producer of cannabis and cannabis-derived products headquartered in Moncton, New Brunswick. Founded in 2013, the company has established a portfolio that spans dried flower, pre-rolls, oils, edibles, and concentrates for both medical and adult-use markets. Organigram operates state-of-the-art indoor and hybrid greenhouse cultivation facilities, which utilize advanced lighting and climate control technologies to optimize yield consistency and product quality.

Since commencing commercial production in 2015, Organigram has focused on expanding its product lines and production capacity. The company’s premium brands, including Organigram, Edison Cannabis Co., and Trailblazer, address diverse consumer preferences across potency levels, formats, and price points. Organigram’s SunSet Farms greenhouse, launched in 2020, added significant square footage to its cultivation footprint, enabling the company to supply wholesalers and retailers coast-to-coast in Canada.

Beyond its domestic footprint, Organigram has pursued international opportunities under Good Manufacturing Practice (GMP) certification, targeting medicinal markets in Europe and other regulated jurisdictions. Memoranda of understanding and supply agreements with overseas distributors have positioned the company to export pharmaceutical-grade cannabis products once regulatory approvals are secured. Organigram also invests in research and development initiatives aimed at novel cannabinoid formulations and delivery systems.

Organigram’s leadership team is led by CEO Greg Engel, who has brought over two decades of consumer goods and cannabis industry experience to the organization. Supporting him are President and COO Lisa Campbell, CFO Eric McClure, and Chief Science Officer Dr. Robert Myers, each overseeing key operational, financial, and scientific functions. The board of directors comprises industry veterans and former government officials who guide corporate governance, strategic direction, and risk management practices.

Key Stats

• Today's Range: $1.44 to $1.47
• 50-Day Range: $1.10 to $1.47
• 52-Week Range: $0.85 to $2.08
• Volume: 769,488 shs
• Average Volume: 665,011 shs
• Market Capitalization: $194.21 million
• P/E Ratio: 14.50
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

Organigram Global Stock Analysis - MarketRank™

Organigram Global scored higher than 19% of companies evaluated by MarketBeat, and ranked 856th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Organigram Global.

Earnings and Valuation

• Score: 2.5 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Organigram Global are expected to grow in the coming year, from ($0.19) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Organigram Global is 14.50, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.91.

Price to Earnings Ratio vs. Sector

The P/E ratio of Organigram Global is 14.50, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 27.96.

Price to Book Value per Share Ratio

Organigram Global has a P/B Ratio of 0.70. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.22% of the float of Organigram Global has been sold short.

Short Interest Ratio / Days to Cover

Organigram Global has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Organigram Global has recently decreased by 4.58%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Organigram Global does not currently pay a dividend.

Dividend Growth

Organigram Global does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

6.22% of the float of Organigram Global has been sold short.

Short Interest Ratio / Days to Cover

Organigram Global has a short interest ratio ("days to cover") of 10.3, which indicates bearish sentiment.

Change versus previous month

Short interest in Organigram Global has recently decreased by 4.58%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.5 / 5
• News Sentiment: 0.54

News Sentiment

Organigram Global has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.00 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Organigram Global this week, compared to 1 article on an average week.

Search Interest

4 people have searched for OGI on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

Only 2 people have added Organigram Global to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Organigram Global insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.09% of the stock of Organigram Global is held by insiders.

Percentage Held by Institutions

Only 34.63% of the stock of Organigram Global is held by institutions.

OGI Stock Analysis - Frequently Asked Questions

How have OGI shares performed this year?

Organigram Global's stock was trading at $1.61 on January 1st, 2025. Since then, OGI stock has decreased by 9.9% and is now trading at $1.45.

How were Organigram Global's earnings last quarter?

Organigram Global Inc. (NASDAQ:OGI) issued its quarterly earnings data on Tuesday, February, 11th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.02. Organigram Global had a negative trailing twelve-month return on equity of 5.93% and a net margin of 8.05%.
Read the conference call transcript.

When did Organigram Global's stock split?

Organigram Global shares reverse split on Friday, July 7th 2023.The 1-4 reverse split was announced on Friday, July 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 25 shares after the split.

Who are Organigram Global's major shareholders?

Top institutional investors of Organigram Global include Baader Bank Aktiengesellschaft (0.19%).

How do I buy shares of Organigram Global?

Shares of OGI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Organigram Global own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Organigram Global investors own include i3 Verticals (IIIV), Ford Motor (F), Lucid Group (LCID), Trade Desk (TTD), Finance of America Companies (FOA), NVIDIA (NVDA) and

Company Calendar

• Last Earnings: 2/11/2025
• Today: 7/11/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 9/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:OGI
• CIK: 1620737
• Web: www.organigram.ca
• Phone: (844) 644-4726
• Fax: N/A
• Employees: 860
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): $0.10
• Trailing P/E Ratio: 14.50
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$33.39 million
• Net Margins: 8.05%
• Pretax Margin: 8.17%
• Return on Equity: -5.93%
• Return on Assets: -4.39%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.42
• Quick Ratio: 1.90

Sales & Book Value

• Annual Sales: $117.47 million
• Price / Sales: 1.65
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.07 per share
• Price / Book: 0.70

Miscellaneous

• Outstanding Shares: 133,940,000
• Free Float: 133,818,000
• Market Cap: $194.21 million
• Optionable: Optionable
• Beta: 1.36